

AGENDA
Clinical Experts Meeting on Lymphatic Filariasis
Organized by Drugs for Neglected Diseases *initiative* and Indian Council of Medical Research
ICMR Conference Hall, New Delhi, India
22 & 23 February 2016

Meeting Objectives:

- To identify the unmet medical needs for the treatment of Lymphatic Filariasis (LF) patients in Asia
- To define the Target Product Profile (TPP) for LF case management in Asia

DAY 1

OPENING SESSION		
09:00 to 09:10	Welcome	Dr. Suman Rijal, Director DNDi India office
09:10 to 09:25	The Drugs for Neglected Diseases (DNDi Model and DNDi R&D overview	Dr. Graeme Bilbe, R&D Director, DNDi
09:25 to 09:40	DNDi Filariasis program Objectives and Meeting Agenda	Dr. Claudia Pena Rossi, Head, Filarial Program, DNDi
09:40 to 10:00	Indian Council of Medical Research (ICMR) activities on Filariasis	Dr. Rashmi Arora, Head, Division of Epidemiology & Communicable Diseases, ICMR
10:00 to 10:30	Opening Remarks	Dr. A C Dhariwal, Director, National Vector Borne Disease Control Program Dr. Swarup Kumar Sarkar, Director Communicable Disease, WHO-SEARO Dr. Soumya Swaminathan , Director General, ICMR
10:30 to 10:45	TEA BREAK	
SESSION 1: Burden of LF in 2015 and estimated projections 2020-2025		
Objective: To describe the current LF burden and the estimates for 2020-2025		
Chairperson: Dr. A C Dhariwal, Director, National Vector Borne Disease Control Program		
10:45 to 11:00	LF Epidemiology and Global Control Program	Dr. Ahmed Jamsheed Mohamed, Medical Officer-VBN WHO Regional Office for South-East Asia
11:00 to 11:15	LF in India: Current burden and control program progress	Dr. P K Srivastava, LF India National Program, NVBDCP
11:15 to 11:30	PacELF - Eliminating lymphatic filariasis in the Asia Pacific	Prof. Kazuyo Ichimori, Professor, Institute of Tropical Medicine, Nagasaki University.
11:30 to 11:45	Projected LF prevalence (infection and morbidity) in 2020-2025	Dr. Wilma Stock, Senior Researcher/Epidemiologist. Erasmus MC University Medical Center Rotterdam
11:45 to 12:30	General discussions and conclusions on future burden of LF	

12:30 to 1:30	LUNCH	
SESSION 2: LF pathogenesis, clinical manifestations and diagnosis in Asia		
Objectives: To describe the pathogenesis and clinical manifestations of LF To describe current diagnostic methods Chairperson: Dr. R C Mahajan, Emeritus Scientist, PGIMER		
1:30 to 1:45	Pathogenesis of LF	Dr. V. Kumaraswami. Former Director of Tuberculosis Research center, Chennai, India.
1:45 to 2:00	Diagnosis	Dr. Gary Weil. Professor, Washington University School of Medicine
2:00 to 2:15	Clinical manifestations and patient categories	Dr. Suma TK. Prof of Internal Medicine, Medical College Hospital, Alappuzha, Kerala
2:15 to 3:15	General discussions and conclusion on patient subpopulations	
3:15 to 3:30	TEA BREAK	
SESSION 3: LF Treatment		
Objective: To identify the unmet medical needs and determine if new therapies are needed Chairperson: Dr N K Ganguly, Advisor & Professor, Translational Health Science & Technology Institute		
Current LF treatments		
3:30 to 3:45	Efficacy of current treatments on LF morbidity	Dr. Suma TK. Prof. of Internal Medicine. Medical College Hospital, Alappuzha, Kerala
3:45 to 4:00	Efficacy of current treatments on the parasite (micro and macrofilaricidal effect)	Dr. K. Ramaiah Consultant LF
New treatments under investigation		
4:00 to 4:15	Preliminary results of current clinical trials on LF	Dr. Gary Weil. Professor Washington University School of Medicine
4:15 to 4:30	Doxycycline effect on the LF parasites and on morbidity.	Dr. Alex Debrah. Parasitology lecturer at Kwame Nkrumah University of Science and Technology (KNUST)
4:30 to 4:45	Studies on new treatments on Filariasis in India.	Dr. Jambulingam, Scientist G & Director - Vector Control Research Centre
4:45 to 5:45	General discussions and conclusion on main efficacy gaps	
7:00 pm onwards	MEETING DINNER	

DAY 2

SESSION 4: TPP for LF case management		
Objective: Define the TPP for LF case management Chairperson: Dr. Nilima Kshirsagar, National chair in Clinical Pharmacology, ICMR		
9:00 to 9:20	Patients perspective	Dr Mitali Mohanty from the LEPRAs Society. Project director of the LF programme in Puri district, Odisha.
9:20 to 9:35	Presentation of the results of the survey done among physicians treating patients	Dr. Thomas John, DNDi consultant
9:35 to 9:45	Questions	
9:45 to 10:00	Introduction TPP (DNDi)	Dr. Nathalie Strub-Wourgaft, Medical Director, DNDi
10:00 to 10:15	TEA BREAK	
10:15 to 11:45	Defining the TPP	2 Panels, composed of a moderator and 3-4 clinicians who see patients, followed by a discussion Moderator panel 1: Dr. A. C. Dhariwal Director, National Vector Borne Disease Control Program (TBC) Panelists: Moderator panel 2: Dr. Rashmi Arora, Head, Division of Epidemiology & Communicable Diseases, ICMR (TBC) Panelists:
11:45 to 12:15	Presentation Panel 1 and general discussion	
12:15 to 12:45	Presentation Panel 2 and general discussion	
12:45 to 1:00	Conclusion	Dr Suman Rijal, Director, DNDi, India
1:00 to 2:00	LUNCH	